S K Pruitt
Overview
Explore the profile of S K Pruitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh U, Cui Y, Dimaano N, Mehta S, Pruitt S, Yearley J, et al.
Biotech Histochem
. 2018 Jun;
93(6):411-423.
PMID: 29863904
Tumor infiltrating lymphocytes (TIL), especially T-cells, have both prognostic and therapeutic applications. The presence of CD8+ effector T-cells and the ratio of CD8+ cells to FOXP3+ regulatory T-cells have been...
2.
Raj G, Pruitt S, Lilly S, Madden J, Price D
J Urol
. 2001 Mar;
165(4):1202.
PMID: 11257672
No abstract available.
3.
Heiser A, Maurice M, Yancey D, Wu N, Dahm P, Pruitt S, et al.
J Immunol
. 2001 Feb;
166(5):2953-60.
PMID: 11207244
Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study,...
4.
White D, Schuler F, Pruitt S, Culhane D, Seigler H, Coleman R, et al.
Surgery
. 1999 Aug;
126(2):156-61.
PMID: 10455878
Background: Sentinel lymph node (SLN) mapping is an effective technique for staging patients with melanoma. In an attempt to avoid reinjection of radiolabeled colloid and facilitate SLN mapping at the...
5.
Dong X, Dematos P, Fong T, Pruitt S, Seigler H
J Surg Oncol
. 1999 Jun;
71(1):36-45.
PMID: 10362090
Background And Objectives: Vaccination with cytokine gene-modified tumor cells augments the immune response against established tumors and protects against tumor challenges. In this study, we investigated the vaccine potential of...
6.
Pruitt S, Bollinger R, Collins B, Marsh Jr H, Levin J, Rudolph A, et al.
Transplantation
. 1997 Mar;
63(6):900-2.
PMID: 9089232
A single bolus of soluble complement (C) receptor type 1 (sCR1, TP-10) has been shown to delay hyperacute rejection (HAR) of porcine cardiac xenografts (Xgs) by primate recipients. In these...
7.
Davis E, Jakobs F, Pruitt S, Greene P, Qian Z, Lam T, et al.
Transplant Proc
. 1997 Feb;
29(1-2):938-9.
PMID: 9123595
No abstract available.
8.
Davis E, Pruitt S, Greene P, Ibrahim S, Lam T, Levin J, et al.
Transplantation
. 1996 Oct;
62(7):1018-23.
PMID: 8878398
Complement (C) inhibition alone using a recombinant soluble form of complement receptor type 1 (sCR1) prevents hyperacute rejection but not subsequent irreversible accelerated acute rejection of discordant pig-to-cynomolgus monkey cardiac...
9.
Pruitt S, Bollinger R, Collins B, Marsh H, Levin J, Rudolph A, et al.
Transplant Proc
. 1996 Apr;
28(2):756.
PMID: 8623382
No abstract available.
10.
Pruitt S, Baldwin 3rd W, Sanfilippo F
Transplant Proc
. 1996 Apr;
28(2):596.
PMID: 8623292
No abstract available.